VALID: Vascular Access Outcome Measure for Function: a vaLidation Study In haemoDialysis

Sponsor
The University of Queensland (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03969225
Collaborator
Australasian Kidney Trials Network (Other)
702
10
32.9
70.2
2.1

Study Details

Study Description

Brief Summary

A functioning vascular access provides a lifeline for patients requiring haemodialysis but vascular access dysfunction remains one of the leading causes of excessive morbidity, mortality and healthcare costs in this group. Despite increasing numbers of vascular access trials, successful interventions to improve vascular access function have been sparse and compromised by highly variable, often selectively reported outcome measures of limited relevance to patients and health professionals. Through engagement of all relevant stakeholders including patients and caregivers, vascular access function, defined by the need for interventions to enable and maintain the use of a vascular access for haemodialysis, has been identified as one of the most critically important outcome measures for trials in haemodialysis. This prospective, multi-centre, multinational validation study aims to assess the accuracy and feasibility of measuring vascular access function part of routine clinical practice and across different clinical settings to ensure successful global implementation of this core outcome measure in future trials in haemodialysis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Haemodialysis is the most common treatment for patients with end-stage kidney disease worldwide and can only be provided via a functional vascular access. Patients, caregivers and health professionals consider vascular access function one of the most critically important outcomes in haemodialysis but trial-based evidence to improve vascular access function is limited by the inconsistent and selective reporting of this outcome. Reporting of a standardised outcome measure for vascular access function across all trials in haemodialysis will enhance the consistency and relevance of trial evidence to guide patient-centred care. Based on international contribution of all relevant stakeholders including patients, the need of interventions to enable and maintain the use of a vascular access for haemodialysis was considered a simple, pragmatic, and meaningful measure of vascular access function. To ensure global implementation across all trial in haemodialysis, it needs to be feasible to accurately collect this outcome measure as part of routine clinical practice without requiring additional resources or expertise in vascular access.

    VALID is a prospective, multi-centre, multinational validation study to assess the accuracy and feasibility of measuring vascular access function, defined by the need for interventions to enable and maintain the use of a vascular access for haemodialysis by clinical staff as part of their routing clinical practice and across different clinical settings.

    The primary objective of the VALID study is to determine whether vascular access function can be measured accurately by clinical staff as part of routine clinical practice compared to the reference standard of a research team with expertise in vascular access during a 6-month follow-up period.

    An estimated 612 participants will be recruited from approximately 10 dialysis units of difference size, type (home-, in-centre and satellite), governance (private versus public), and location (rural versus urban) across Australia, Canada, China, France, United Kingdom, Netherlands, Malaysia and the United States of America (USA).

    Implementation of a validated outcome measure for vascular access function across clinical trials will improve the reliability, comparability and relevance of future research in haemodialysis to inform patient-centred care.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    702 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Vascular Access Outcome Measure for Function: a vaLidation Study In haemoDialysis (VALID)
    Actual Study Start Date :
    Dec 6, 2019
    Actual Primary Completion Date :
    Jun 30, 2022
    Anticipated Study Completion Date :
    Sep 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Reporting of vascular access function, defined by the need for any intervention(s) required to enable and maintain the use of a vascular access for haemodialysis. Vascular access interventions to be collected are outlined in the description below. [6 months]

      Arteriovenous fistula (AVF)/Arteriovenous graft (AVG) Open surgical or endovascular creation/placement of AVF/AVG Open surgical revision or endovascular intervention of AVG/AVF Thrombolysis or thrombectomy of AVG/AVF Ligation or resection of arteriovenous access Repair of aneurysm/pseudoaneurysm Competing/collateral vein ligation Fistulogram (Angiogram) +/- angioplasty +/- stenting (including inflow artery, body of AVF/AVG, venous outflow, central vein) Competing/collateral vein embolisation Superficialisation/transposition Management of Dialysis Associated Steal Syndrome (DASS)/Access Induced Ischaemia. Procedures include: Distal Revascularisation, Interval Ligation (DRIL) Proximalisation of the Arterial Inflow (PAI) Revision Using Distal Inflow (RUDI) Banding Central venous catheter (CVC) CVC insertion CVC exchange Fibrin sheath removal/disruption CVC removal

    Secondary Outcome Measures

    1. Rate of vascular access interventions to enable and maintain the use of a vascular access for haemodialysis (number/patient-year). [6 months]

      Interventions collected as listed in the Primary Outcome description

    2. Time to first vascular access intervention to enable and maintain the use of a vascular access for haemodialysis (days). [6 months]

      Interventions collected as listed in the Primary Outcome description

    3. Type of vascular access interventions. [6 months]

      Interventions collected as listed in the Primary Outcome description

    Other Outcome Measures

    1. Time required for measuring vascular access function (minutes) [6 months]

      Feasibility outcome measures

    2. Completeness of data collection (percentage) [6 months]

      Feasibility outcome measures

    3. Likert score of feasibility questionnaire with data collectors (scale of 1 to 5, 1=strongly disagree, 5=strongly agree) [6 months]

      Feasibility outcome measures

    4. Qualitative analysis of semi structured interview with data collector [6 months]

      Feasibility outcome measures

    5. Recruitment rate (number of participants/year) [6 months]

      Feasibility outcome measures

    6. Eligibility ratio (number of patients eligible/number of patients screened) [6 months]

      Feasibility outcome measures

    7. Enrolment ratio (number of patients enrolled/number of patients screened) [6 months]

      Feasibility outcome measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients new to or established on chronic haemodialysis (i.e. incident and prevalent patients on chronic haemodialysis)

    • Patients 18 years or more of age

    • Able to provide informed consent (if consent is required).

    Exclusion Criteria:
    • Anticipated to require haemodialysis for less than 90 days

    • Treating team considers patient unsuitable to be enrolled

    • Patient or authorised representative not willing to consent (if consent is required).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Princess Alexandra Hospital Brisbane Queensland Australia 4110
    2 Mackay Hospital Mackay Queensland Australia 4740
    3 Mater Hospital Brisbane Australia
    4 Hervey Bay Hospital Hervey Bay Australia
    5 University Health Network Toronto Canada
    6 Centre Hospitalier RĂ©gional Universitaire de Tours Tours France
    7 Hospital Sultanah Aminah Johor Bahru Johor Bahru Malaysia
    8 Maastricht University Medical Centre Maastricht Netherlands
    9 Ospedale Regionale di Lugano Lugano Switzerland
    10 Sheffield Teaching Hospital Sheffield United Kingdom

    Sponsors and Collaborators

    • The University of Queensland
    • Australasian Kidney Trials Network

    Investigators

    • Principal Investigator: Andrea Viecelli, MD, FRAC, Princess Alexandra Hospital and Australasian Kidney Trials Network

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    The University of Queensland
    ClinicalTrials.gov Identifier:
    NCT03969225
    Other Study ID Numbers:
    • AKTN 19.01
    First Posted:
    May 31, 2019
    Last Update Posted:
    Aug 5, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by The University of Queensland

    Study Results

    No Results Posted as of Aug 5, 2022